Cisplatin-induced renal toxicity: Possible reversal by N-acetylcysteine treatment

Journal of the American Society of Nephrology

Volumn 8, Issue 10, 1997, Pages 1640-1645

  Sheikh Hamad, David ^a   Timmins, Katherine ^a   Jalali, Ziba ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CISPLATIN;

ADULT; ARTICLE; BLINDNESS; BONE MARROW SUPPRESSION; CASE REPORT; DRUG OVERDOSE; FEMALE; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; NEPHROTOXICITY; OTOTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL;

EID: 0030720871     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakof IH: High dose cis-platinum diammine dichloride: Amelioration of renal toxicity by mannitol diuresis. Cancer 39: 1372-1381, 1977
2. Womer RB, Pritchard J, Barratt TM: Renal toxicity of cisplatin in children. J Pediatr 106: 659-663, 1985
3. Ostrow S, Egorin MJ, Hahn D, Markus S, Aisner J, Chang P, LeRoy A, Bachur NR, Wiernik OH: High-dose cisplatin therapy using mannitol versus furosemide diuresis: Comparative pharmacokinetics and toxicity. Cancer Treat Rep 65: 73-78, 1981
4. Nanji AA, Stewart DJ, Mikhael NZ: Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol 17: 274-276, 1986
5. Appenroth D, Winnefeld K, Schroter H, Rost M: Beneficial effect of acetylcysteine on cisplatin nephrotoxicity in rats. J Appl Toxicol 13: 189-192, 1993
6. Chu G, Mantin R, Shen YM, Baskett G, Sussman H: Massive cisplatin overdosage by accidental substitution for carboplatin. Toxicity and management. Cancer 72: 3707-3714, 1993
7. Campbell AB, Kalman SM, Jacobs C: Plasma platinum levels: Relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67: 169-172, 1983
8. Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH: Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41: 1274-1281, 1978
9. Litterst CL, Torres IJ, Guarino AM: Plasma levels and organ distribution of platinum in the rat, dog, and dogfish shark following single intravenous administration of cis-dichloro-diammineplatinum(II). J Clin Hematol Oncol 7: 169-179, 1977
10. Appenroth D, Winnefeld K: Role of glutathione for cisplatin nephrotoxicity in young and adult rats. Renal Failure 15: 135-139, 1993
11. Appenroth D, Braunlich H: Age differences in cisplatinum nephrotoxicity. Toxicology 32: 343-353, 1984
12. Dobyan DC, Levi J, Jacobs C, Kosec J, Weiner MW: Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther 213: 551-556, 1980
13. Offerman JJG, Meijer S, Sleijfer DT, Mulder NH, Donker AJM, Koops SH, Van Der Hem GK: Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function. Cancer Chemother Pharmacol 12: 36-38, 1984
14. Dobyan DC, Hill D, Lewis T, Bulger RE: Cyst formation in rat kidney induced by cisplatinum administration. Lab Invest 45: 260-268, 1981
15. Du Bois A, Hasenfratz R, Zimmerhackl LB, De Broe ME, Niederle N, Neerpohl HG: Cisplatin and carboplatin induced acute, cumulative and chronic nephrotoxicity [Meeting Abstract]. Proc Ann Meet Am Assoc Cancer Res 35: A1475, 1994.
16. Cohen AI, Harberg J, Citrin DL: Measurement of urinary beta 2-microglobulin in the detection of cisplatin nephrotoxicity. Cancer Treat Rep 65: 1083-1085, 1981
17. Soejima A, Inoue T, Suzuki M, Waku M, Nakabayashi K, Kitamoto K, Nagasawa T: Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer. Jpn J Nephrol 34: 801-806, 1992
18. Repta AJ, Long DF: Reactions of cisplatin with human plasma and plasma fractions. In: Cisplatin: Current Status and New Development, edited by Prestayko AW, Crooke ST, Carter SK, assisted by Alder NA, New York, Academic Press, 1980, pp 285-304
19. Levi J, Jacobs C, Kalman SM, McTigue M, Weiner MW: Mechanism of cis-platinum nephrotoxicity. I. Effects of sulfhydryl groups in rat kidneys. J Pharmacol Exp Ther 213: 545-550, 1980
20. Anderson ME, Naganuma A, Meister A: Protection against cisplatin toxicity by administration of glutathione ester. FASEB J 4: 3251-3255, 1990
21. Daley-Yates PT, McBrien DCH: Cisplatin metabolites: A method for their separation and for measurement of their renal clearance in vivo. Biochem Pharmacol 32: 181-184, 1983
22. Jones MM, Basinger MA, Holscher MA: Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity. Toxicology 68: 227-247, 1991
23. Reznick LV, Myazina EM, Shakchmatova EI, Gambaryan SP, Brovtsyn VK, Natochin YV, Jones MM: The prevention of cisplatin-induced renal dysfunction by hydroxyl-containing dithiocarbamates. Br J Cancer 63: 234-236, 1991
24. Reznick LV, Gambaryan SP, Jones MM: The effect of hydroxyl-containing dithiocarbamates on cisplatin-induced long-term renal dysfunction in Wistar rats. Toxicology 83: 79-91, 1993
25. Litterst CL, Tong S, Hirokata Y, Siddik ZH: Alterations in hepatic and renal levels of glutathione and activities of glutathione s-transferases from rats treated with cis-dichlorodiammin-eplatinum-II. Cancer Chemother Pharmacol 8: 67-71, 1982
26. Pfeifle CE, Howell SB, Felthouse RD, Woliver TB, Andrews PA, Markman M, Murphy MP: High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 3: 237-244, 1985
27. Zunio F, Pratesi G, Micheloni A, Caralletti E, Sala F, Tofanetti O: Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70: 89-101, 1989
28. Baldew GS, Mol JG, DeKanter FJ, Van Baar B, De Goeij JJ, Vermeulen NP: The mechanism of interaction between cisplatin and selenite. Biochem Pharmacol 41: 1429-1437, 1991
29. Aggarwal SK: A histochemical approach to the mechanism of action of cisplatin and its analogues. J Histochem Cytochem 41: 1053-1073, 1993
30. Uozumi J, Ueda T, Yasumasu T, Koikawa Y, Kumazawa J: Calcium blockers enhance cisplatin-induced nephrotoxicity in rats. Int Urol Nephrol 24: 549-553, 1992
31. Heyman SN, Rosen S, Silva P, Spokes K, Egorin MJ, Epstein FH: Protective action of glycine in cisplatin nephrotoxicity. Kidney Int 40: 273-279, 1991
32. Umeki S, Tsukiyama K, Okimoto N, Soejima R: Urinastatin (Kunitz-type proteinase inhibitor) reducing cisplatin nephrotoxicity. Am J Med Sci 298: 221-226, 1989
33. Brillet G, Deray G, Lucsko M, Faucher C, Aubert P, Rottembourg J, Jacobs C: Definitive end-stage chronic kidney failure after cisplatin treatment. Nephrologie 14: 227-229, 1993